Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) have been given an average recommendation of “Moderate Buy” by the twenty-seven brokerages that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and twenty-two have given a buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $490.9604.

A number of equities research analysts recently weighed in on ALNY shares. Morgan Stanley upped their price objective on Alnylam Pharmaceuticals from $405.00 to $475.00 and gave the stock an “equal weight” rating in a research note on Monday, October 6th. Raymond James Financial reissued an “outperform” rating and set a $472.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday. Wall Street Zen upgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday, November 10th. Wells Fargo & Company lifted their price objective on shares of Alnylam Pharmaceuticals from $395.00 to $479.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 11th. Finally, Royal Bank Of Canada boosted their price objective on shares of Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the stock an “outperform” rating in a research note on Friday, September 19th.

Key Stories Impacting Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Needham published a bullish forecast expecting strong price appreciation for ALNY, citing upside from the company’s longer-term growth plan. Needham & Company LLC Forecasts Strong Price Appreciation for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock
• Neutral Sentiment: A Yahoo Finance piece examined Alnylam’s valuation in light of the newly unveiled Alnylam 2030 plan — useful context for investors weighing the company’s premium valuation against projected revenue/profitability milestones. A Look At Alnylam Pharmaceuticals (ALNY) Valuation After Unveiling Its Alnylam 2030 Growth Plan
• Neutral Sentiment: CEO Yvonne Greenstreet discussed development priorities and the path to profitability in a media interview — helpful for understanding management’s messaging but not new data. Alnylam Pharmaceuticals CEO on development goals, profitability
• Negative Sentiment: Bank of America issued a pessimistic forecast for ALNY, adding downward analyst pressure after the guidance/2030 announcement. Bank of America Issues Pessimistic Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price
• Negative Sentiment: Market reaction: a Yahoo report noted ALNY slid sharply after the ambitious 2026 guidance and 2030 plan reveal — indicates investor concern about near-term targets or execution risk. Alnylam Pharmaceuticals (ALNY) Is Down 9.0% After Ambitious 2026 Guidance And 2030 Plan Reveal
• Negative Sentiment: Multiple insiders (including CEO Yvonne Greenstreet and several EVPs) disclosed sizable stock sales on Jan. 12–13, reducing ownership by ~4–11% in individual cases — typically viewed as a negative signal or a source of additional selling pressure. SEC filing example: SEC filing — Yvonne Greenstreet sale

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, EVP Jeffrey V. Poulton sold 2,780 shares of the business’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $362.87, for a total transaction of $1,008,778.60. Following the sale, the executive vice president owned 57,465 shares in the company, valued at approximately $20,852,324.55. The trade was a 4.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Tolga Tanguler sold 1,510 shares of the stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $362.87, for a total transaction of $547,933.70. Following the completion of the transaction, the executive vice president directly owned 29,728 shares of the company’s stock, valued at $10,787,399.36. The trade was a 4.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 56,955 shares of company stock valued at $24,072,733. Corporate insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Brighton Jones LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at $243,000. Geneos Wealth Management Inc. raised its stake in Alnylam Pharmaceuticals by 372.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company’s stock worth $60,000 after acquiring an additional 175 shares during the last quarter. MassMutual Private Wealth & Trust FSB lifted its position in Alnylam Pharmaceuticals by 36.1% during the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 196 shares of the biopharmaceutical company’s stock worth $64,000 after acquiring an additional 52 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd grew its stake in Alnylam Pharmaceuticals by 14.3% during the 2nd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 14,808 shares of the biopharmaceutical company’s stock valued at $4,829,000 after purchasing an additional 1,851 shares during the last quarter. Finally, Swedbank AB increased its holdings in shares of Alnylam Pharmaceuticals by 7.2% in the second quarter. Swedbank AB now owns 64,315 shares of the biopharmaceutical company’s stock valued at $20,972,000 after purchasing an additional 4,322 shares during the period. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 0.8%

Alnylam Pharmaceuticals stock opened at $366.86 on Thursday. Alnylam Pharmaceuticals has a twelve month low of $205.87 and a twelve month high of $495.55. The business has a fifty day moving average of $422.03 and a two-hundred day moving average of $421.56. The firm has a market cap of $48.47 billion, a P/E ratio of 1,528.58 and a beta of 0.32. The company has a quick ratio of 2.49, a current ratio of 2.54 and a debt-to-equity ratio of 4.45.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.